Based on Polymarket prediction data, the current odds are:
Yes
0%
No
0%
Trading volume: $151.8k | Status: Closed
This is a market on whether Pfizer's COVID-19 vaccine will be the first vaccine to receive regulatory approval in the USA, in the form of either FDA approval OR Emergency Use Authorization, whichever comes first. This market will resolve to “Yes” if Pfizer's COVID-19 vaccine receives FDA approval or EUA, before any other COVID-19 vaccine. This market will resolve when the first FDA approval or EUA for a COVID-19 vaccine occurs, and if it is for Pfizer's vaccine, this market will resolve to "Yes", while if it is for any other vaccine, this market will resolve to "No". Note, this market is NOT on if Pfizer's COVID-19 vaccine will be the first FDA approved or the first EUA, but rather if it will be the first vaccine to achieve regulatory approval in either form (FDA approval or EUA). If Pfizer's vaccine gets regulatory approval the same day as 1 or more other vaccines, according to EST, the market will resolve to "No", as this means their vaccine is not definitively *first*. This market will be resolved in good faith, according to the FDA list of licensed vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), the FDA EUA list (https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization), as well as any other resolution source deemed appropriate by the Markets Integrity Committee (MIC).
Whale traders with large portfolios are actively trading this market on Polymarket. These high-volume traders often have access to deep research and move prices when they take positions. Track which wallets are placing large bets on this question and follow their conviction using PredCopy.
View detailed market data, whale activity, and trading volume on the full market page.
View market detailsRisk Disclaimer
Prediction market trading involves substantial risk. Past performance does not guarantee future results. This content is for informational purposes only and should not be considered financial advice. Only trade with funds you can afford to lose.